Quick Answer
Arcturus Therapeutics Holdings Inc. reported Stockholders Equity of $213.99 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -11.2% in Stockholders Equity from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $27.55 million | Q2 2018: $17.80 million | Q3 2018: $14.15 million | Q1 2019: $6.35 million | Q2 2019: $21.62 million | Q3 2019: $35.90 million | Q1 2020: $16.98 million | Q2 2020: $93.42 million | Q3 2020: $261.63 million | Q1 2021: $352.61 million | Q2 2021: $305.65 million | Q3 2021: $259.13 million | Q1 2022: $184.75 million | Q2 2022: $170.72 million | Q3 2022: $145.67 million | Q1 2023: $329.25 million | Q2 2023: $285.18 million | Q3 2023: $280.06 million | Q1 2024: $263.97 million | Q2 2024: $258.58 million | Q3 2024: $261.87 million | Q1 2025: $233.76 million | Q2 2025: $231.05 million | Q3 2025: $224.56 million.
- Over the full 9 years of available data (2017 to 2025), Arcturus Therapeutics Holdings Inc.'s Stockholders Equity has grown by 533.2%.
- Historical annual values: Fiscal year 2025: $213.99 million | Fiscal year 2024: $240.98 million | Fiscal year 2023: $278.51 million | Fiscal year 2022: $270.31 million | Fiscal year 2021: $228.21 million | Fiscal year 2020: $396.55 million | Fiscal year 2019: $25.79 million | Fiscal year 2018: $13.64 million | Fiscal year 2017: $33.79 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: